CHORDIA THERAPEUTICS INC (190A.T)
JPY 214.0
(-12.65%)
JPY 214.0
(-12.65%)
| Breakdown | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | -1.93 Billion | 543.73 Million | -1.7 Billion | -544.58 Million |
| Net Income | -1.82 Billion | 223.34 Million | -1.77 Billion | -527.1 Million |
| Depreciation & Amortization | 4.09 Million | 6.04 Million | 3.14 Million | 700 Thousand |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | - | - | 24.52 Million | 11.54 Million |
| Change in working capital | -128.32 Million | 312.52 Million | 69.91 Million | -50.63 Million |
| Other non-cash items | 14.11 Million | 13.9 Million | 8.16 Million | 33.85 Million |
| Investing Cash Flow | -10.95 Million | 345 Thousand | -14.69 Million | -2.36 Million |
| Investments in PPE | -537 Thousand | -723 Thousand | -13.54 Million | -2.33 Million |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | -10.42 Million | 1.06 Million | -1.15 Million | -29 Thousand |
| Financing Cash Flow | 1.47 Billion | - | 3.97 Billion | 1.52 Billion |
| Debt repayment | - | - | - | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 1.47 Billion | - | 3.97 Billion | 1.52 Billion |
| Other Financing Activities | - | - | - | 1000.00 |
| Accounts receivables | - | - | - | - |
| Accounts payables | - | - | - | - |
| Inventory | - | - | - | - |
| Other working capital | -128.32 Million | 312.52 Million | 69.91 Million | -50.63 Million |
| Cash at beginning of period | 4.79 Billion | 4.25 Billion | 1.99 Billion | 1.01 Billion |
| Cash at end of period | 4.32 Billion | 4.79 Billion | 4.25 Billion | 1.99 Billion |
| Capital Expenditure | -537 Thousand | -723 Thousand | -13.54 Million | -2.33 Million |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | -469.41 Million | 544.07 Million | 2.25 Billion | 978.96 Million |
| Free Cash Flow | -1.93 Billion | 543 Million | -1.71 Billion | -546.91 Million |
| Breakdown | 2023 FY | 2022 FY | 2021 FY |
|---|---|---|---|
| Operating Cash Flow | - | - | - |
| Net Income | 223.34 Million | -1.77 Billion | -527.1 Million |
| Depreciation & Amortization | 6.04 Million | 3.14 Million | 700 Thousand |
| Deferred income taxes | - | - | - |
| Stock-based compensation | - | 24.52 Million | 11.54 Million |
| Change in working capital | 312.52 Million | 69.91 Million | -50.63 Million |
| Other non-cash items | 13.9 Million | 8.16 Million | 33.85 Million |
| Investing Cash Flow | 345 Thousand | -14.69 Million | -2.36 Million |
| Investments in PPE | -723 Thousand | -13.54 Million | -2.33 Million |
| Acquisitions | - | - | - |
| Investment purchases | - | - | - |
| Sales/Maturities of investments | - | - | - |
| Other Investing Activities | 1.06 Million | -1.15 Million | -29 Thousand |
| Financing Cash Flow | - | 3.97 Billion | 1.52 Billion |
| Debt repayment | - | - | - |
| Dividends payments | - | - | - |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | - | 3.97 Billion | 1.52 Billion |
| Other Financing Activities | - | - | 1000.00 |
| Accounts receivables | - | - | - |
| Accounts payables | - | - | - |
| Inventory | - | - | - |
| Other working capital | 312.52 Million | 69.91 Million | -50.63 Million |
| Cash at beginning of period | 4.25 Billion | 1.99 Billion | 1.01 Billion |
| Cash at end of period | 4.79 Billion | 4.25 Billion | 1.99 Billion |
| Capital Expenditure | -723 Thousand | -13.54 Million | -2.33 Million |
| Effect of forex changes on cash | - | - | - |
| Net cash flow / Change in cash | 544.07 Million | 2.25 Billion | 978.96 Million |
| Free Cash Flow | 543 Million | -1.71 Billion | -546.91 Million |
005810
MYLKF
3111
HDSN
7460
9145